Adriamycin in advanced bronchogenic carcinoma

Engracio P. Cortes, Hiroshi Takita, James F. Holland

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Adriamycin, a new cytotoxic antibiotic with antitumor activity in a variety of neoplasms, was given to 31 patients with advanced bronchogenic carcinoma. The doses used were 30 and 35 mg/m2 of body surface area daily for 3 days repeated at 3‐ or 4‐week intervals. Objective regression (<50%) was seen in 4 of 20 patients receiving 30 mg/m2 and 5 of 11 patients receiving 35 mg/m2. Regressions according to histologic cell type were seen in 5 of 17 adenocarcinomas, 3 of 6 small cell carcinomas, 1 of 6 large cell anaplastic carcinomas, and 0 of 2 squamous cell carcinomas. Those patients who attained tumor regression survived longer than those who had progression. Toxic manifestations of Adriamycin administration were myelosuppression, stomatitis, cardiomyopathy, and nausea and vomiting. Adriamycin at doses below the cumulative cardiotoxic threshold appears to be of clinical value in advanced bronchogenic carcinoma.

Original languageEnglish
Pages (from-to)518-525
Number of pages8
JournalCancer
Volume34
Issue number3
DOIs
StatePublished - Sep 1974
Externally publishedYes

Fingerprint

Dive into the research topics of 'Adriamycin in advanced bronchogenic carcinoma'. Together they form a unique fingerprint.

Cite this